While often used interchangeably, Dementia and Alzheimer’s disease are not the same thing. 

​

The Core Difference

• Dementia is an umbrella term (like "heart disease") used to describe a set of symptoms, such as memory loss and difficulties with thinking, that are severe enough to interfere with daily life.

• Alzheimer’s Disease is a specific brain disease and is the most common cause of dementia, accounting for 60% to 80% of all cases. 

  ​

Common Types of Dementia

Dementia can be caused by various underlying diseases that damage brain cells: 

• Alzheimer's Disease: Characterized by plaques and tangles in the brain; typically begins with difficulty remembering new information.

• Vascular Dementia: The second most common type, caused by strokes or other conditions that block blood flow to the brain.

• Lewy Body Dementia: Caused by abnormal protein deposits (Lewy bodies) in the brain; often involves visual hallucinations and sleep disturbances.

• Frontotemporal Dementia (FTD): Primarily affects the front and sides of the brain; often leads to dramatic changes in personality and behavior.

• Mixed Dementia: Occurs when a person has brain changes from more than one type of dementia simultaneously (most commonly Alzheimer's and vascular dementia). 

  ​

Early Warning Signs

While symptoms vary by type, general early signs of cognitive decline include: 

• Memory Loss: Forgetting recently learned information or important dates.

• Difficulty with Tasks: Struggling to complete familiar chores, such as following a recipe or managing bills.

• Confusion: Losing track of dates, seasons, or the passage of time.

• Mood Changes: Becoming unusually confused, suspicious, depressed, fearful, or anxious. 

​

​​​​Recent medical research (2024–2025) suggests that Hyperbaric Oxygen Therapy (HBOT) is an effective and safe intervention for improving cognitive function and potentially slowing the progression of Alzheimer’s disease and other dementias. While not yet FDA-approved for this specific indication, it is frequently used "off-label" to address the vascular and inflammatory components of neurodegeneration. 

​

Clinical Evidence and Study Outcomes

A comprehensive 2024 meta-analysis of 11 randomized controlled trials (847 participants) found that HBOT significantly improved several key metrics for Alzheimer's (AD) patients: 

• Cognitive Scores: Notable improvements in Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale-Cognitive (ADAS-Cog) scores.

• Daily Living: Patients showed enhanced ability to perform Activities of Daily Living (ADL) compared to those receiving standard care alone.

• Brain Metabolism: PET scans have documented up to a 38% increase in brain metabolism and regional blood flow following structured HBOT protocols (e.g., 40–60 sessions). 

  ​

Biological Mechanisms

HBOT targets the "root" biological drivers of dementia by addressing more than just symptoms: 

• Amyloid and Tau Reduction: Evidence from animal and pilot human studies indicates HBOT can induce the clearance of existing amyloid plaques and reduce tau protein aggregation.

• Increased Blood Flow: By stimulating angiogenesis (new blood vessel growth), HBOT increases cerebral blood flow by 16–23%, reversing the chronic hypoxia (oxygen starvation) typical in aging brains.

• Neuroinflammation Suppression: Treatment has been shown to reduce inflammatory cytokines like IL-1β and TNF-α while reducing the activation of harmful glial cells.

• Neuroplasticity: The high-pressure environment enhances the brain's ability to "rewire" itself and re-activate idling neurons. 

  ​​